FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics

MHRA strengthens safety warnings for finasteride and dutasteride

Inoculation: A Vaccine Against Anti-vaccine Arguments

Combination therapy and its resistance in the development of antimalarial drugs

Cardiac Safety of Intranasal Chlorpheniramine: An Exposure-Based Risk Assessment

Drug Safety for Lactating Women: Still a Forgotten Frontier?

Counterfeit anti-rabies vaccine as a neglected issue: a manufacturers’ perspective

ADHD medications and drug withdrawal: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database

Pharmacovigilance and toxicological studies on safety signals associated with the combined use of propofol and midazolam

Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs)

Assessing safety in the RTS,S/AS01 malaria vaccine implementation programme: an overview and comparison of methods

Efficacy and Safety of Digitalis Glycosides in Heart Failure. A Meta-Analysis

Precautionary recall of antidepressant medication due to manufacturing error

La OMS rechaza nuevamente la inclusión del metilfenidato para el TDAH en su lista de medicamentos esenciales

Fake Malaria Drugs Undermine Africa’s Fight

Global crackdown on illicit pharmaceuticals sees USD 15.5 million in seizures

Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics

La AEMPS adecúa los formatos de antibióticos para alinearlos con las pautas clínicas habituales y evitar su uso inapropiado

New Drugs Are Primary Care Game Changers, but Pricey

Comparative Cardiovascular Safety of Prescription Amphetamine and Methylphenidate Initiation Among Older Adult Medicare Beneficiaries

AI Drug Safety in Pregnancy

Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system

Drug-induced neutropenia: A comprehensive pharmacovigilance study of the FAERS database

Identifying High‐Risk Medications for Drug‐Induced Dystonia: A 20‐Year Retrospective Real‐World Pharmacovigilance Study Based on FAERS

Exploring Risk Drugs and Mechanisms in Dystonia: Insights from Pharmacovigilance and Proteogenomics

Boletín sobre Seguridad de Medicamentos de Uso Humano. Febrero de 2026